FAM171A2

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, FAM171A2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FAM171A2 data layer compared with 29 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher FAM171A2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM171A2 expression acts as an unfavorable survival marker.

UCEC are the cancer types where FAM171A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
UCECOSMedianIV0.2310.592.0366view →
Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

FAM171A2–UCEC (OS)

Kaplan–Meier survival curve for FAM171A2 mutant vs wild-type samples in UCEC.

Open the UCEC breakdown →

Exploration